VectivBio Holding AG
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a VECT research report →
Companyvectivbio.com
VectivBio Holding AG, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for treatments of severe rare conditions. It develops apraglutide, a long-acting synthetic peptide analog of glucagon-like peptide-2 that is in Phase III clinical trial for the treatment of patients with short bowel syndrome-intestinal failure (SBS-IF), as well as apraglutide is in Phase II clinical trial for SBS-IF in patients with colon-in-continuity anatomy. The company is also developing apraglutide, which is in Phase II clinical trial for patients with steroid-refractory gastrointestinal acute versus host disease (aGvHD).
- CEO
- Luca Santarelli
- IPO
- 2021
- HQ
- Basel, CH
Price Chart
Valuation
- Market Cap
- $1.06B
- P/E
- -7.94
- P/S
- 38.75
- P/B
- 3.49
- EV/EBITDA
- -10.63
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 100.00%
- Op Margin
- -294.52%
- Net Margin
- -342.84%
- ROE
- -56.92%
- ROIC
- -35.32%
Growth & Income
- Revenue
- $27.34M · 0.00%
- Net Income
- $-93,735,000 · -7.73%
- EPS
- $-2.12 · 34.37%
- Op Income
- $-80,524,000
- FCF YoY
- 21.97%
Performance & Tape
- 52W High
- $16.98
- 52W Low
- $4.25
- 50D MA
- $14.57
- 200D MA
- $9.66
- Beta
- 0.10
- Avg Volume
- 1.10M
Get TickerSpark's AI analysis on VECT
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our VECT Coverage
We haven't published any research on VECT yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate VECT Report →